Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shiu-Nan Chen has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being processed in 1 distinct art unit, indicating a singular focus for the current pharmaceutical innovations. The prosecution is handled by 1 distinct examiner, SUSAN COE HOFFMAN. This concentration of the pending workload into a single art unit and examiner suggests a very specific regulatory path for the innovations at this time.
SUSAN COE HOFFMAN is the busiest examiner for this portfolio, currently managing 1 pending office action. This examiner is the sole individual responsible for the active office action workload. The outcome of the current prosecution cycle is therefore tied to the specific feedback from this one examiner. There is no current opportunity to compare examiner behavior across different applications within this portfolio, as only 1 pending office action exists.
The alignment of 1 pending office action with 1 distinct examiner and 1 distinct art unit suggests a streamlined but narrow prosecution environment. There are no other pending actions or examiners currently involved in the portfolio. Practitioners must address the specific requirements of SUSAN COE HOFFMAN within the 1 distinct art unit. This concentrated activity allows for a dedicated approach to the single application currently under review by the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOFFMAN, SUSAN COE | 1 | 54.2% | +25.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18770143 | APPLICATION OF PURIFIED MUSHROOM BETA GLUCAN IN PREVENTING, IMPROVING OR TREATING ALZHEIMER'S DISEASE, DEMENTIA OR BRAIN FUNCTION DEGENERATION | HOFFMAN, SUSAN COE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18770143 | APPLICATION OF PURIFIED MUSHROOM BETA GLUCAN IN PREVENTING, IMPROVING OR TREATING ALZHEIMER'S DISEASE, DEMENTIA OR BRAIN FUNCTION DEGENERATION | HOFFMAN, SUSAN COE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18770143 | APPLICATION OF PURIFIED MUSHROOM BETA GLUCAN IN PREVENTING, IMPROVING OR TREATING ALZHEIMER'S DISEASE, DEMENTIA OR BRAIN FUNCTION DEGENERATION | HOFFMAN, SUSAN COE | 1655 | §103§112 | Non-Final OA | — | Pending | Jul 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShiu-Nan Chen has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Susan Coe Hoffman has the most, with 1 of Shiu-Nan Chen's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
